A systematic review of bone mineral density and fractures in phenylketonuria
- PMID: 25005329
- PMCID: PMC4208974
- DOI: 10.1007/s10545-014-9735-2
A systematic review of bone mineral density and fractures in phenylketonuria
Abstract
Introduction: Our objective was to systematically review and analyze published data on bone mineral density (BMD) and fracture rates in patients with phenylketonuria (PKU), and relationships between BMD and phenylalanine levels.
Methodology: We searched PubMed, CINAHL, and Cochrane databases from January 1966 to November 2013 for studies of spine BMD or fracture in PKU and control subjects. We excluded studies assessing skeletal health by ultrasound or peripheral quantitative computer tomography. Both authors reviewed abstracts for inclusion, and read full text papers to extract data.
Results: Sixteen studies met eligibility criteria. Meta-analysis of three studies found that spine BMD was 0.100 g/cm(2) lower (95% CI, -0.110, -0.090 g/cm(2)) in 67 subjects with PKU, compared to 161 controls. Among six studies, 20% (53 of 263) of PKU subjects experienced clinical fractures. In the single study with controls, the fracture rate was 2.6 fold higher (95% CI, 1.1-6.1) after age 8 in PKU subjects, compared to healthy sibling controls. When considering a total of 12 studies in 412 subjects, nine or 75% of studies representing 71% of studied subjects reported no association between phenylalanine levels and BMD. Spine BMD is lower in PKU than control subjects, but only one study controlled for smaller body size. Existing studies suggest a clinical fracture rate of 20% among PKU subjects, but fracture rates in controls are lacking. Finally, existing data shows no consistent relationship between phenylalanine levels and BMD. Future studies are needed to clarify the etiology and health consequences of low BMD in PKU.
Conflict of interest statement
Karen Hansen is a consultant to Takeda Pharmaceuticals and Deltanoid Pharmaceuticals.
Denise Ney is a co-inventor on US Patent 8,604,168 B2, Glycomacropeptide Medical Foods for Nutritional Management of Phenylketonuria and other Metabolic Disorders, held by the Wisconsin Alumni Research Foundation and licensed to Cambrooke Therapeutics, LLC.
Figures





Similar articles
-
Effectiveness and safety of vitamin D in relation to bone health.Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088161 Free PMC article.
-
Calcium and vitamin D for increasing bone mineral density in premenopausal women.Cochrane Database Syst Rev. 2023 Jan 27;1(1):CD012664. doi: 10.1002/14651858.CD012664.pub2. Cochrane Database Syst Rev. 2023. PMID: 36705288 Free PMC article.
-
A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management.Health Technol Assess. 2008 Mar;12(3):iii-ix, xi-xiv, 1-208. doi: 10.3310/hta12030. Health Technol Assess. 2008. PMID: 18284894
-
Bone health in phenylketonuria: a systematic review and meta-analysis.Orphanet J Rare Dis. 2015 Feb 15;10:17. doi: 10.1186/s13023-015-0232-y. Orphanet J Rare Dis. 2015. PMID: 25758373 Free PMC article.
-
Steroidal contraceptives: effect on bone fractures in women.Cochrane Database Syst Rev. 2014 Jun 24;2014(6):CD006033. doi: 10.1002/14651858.CD006033.pub5. Cochrane Database Syst Rev. 2014. PMID: 24960023 Free PMC article.
Cited by
-
A bone mineralization defect in the Pahenu2 model of classical phenylketonuria involves compromised mesenchymal stem cell differentiation.Mol Genet Metab. 2018 Nov;125(3):193-199. doi: 10.1016/j.ymgme.2018.08.010. Epub 2018 Aug 27. Mol Genet Metab. 2018. PMID: 30201326 Free PMC article.
-
The complete European guidelines on phenylketonuria: diagnosis and treatment.Orphanet J Rare Dis. 2017 Oct 12;12(1):162. doi: 10.1186/s13023-017-0685-2. Orphanet J Rare Dis. 2017. PMID: 29025426 Free PMC article. Review.
-
Bone health in patients with inborn errors of metabolism.Rev Endocr Metab Disord. 2018 Mar;19(1):81-92. doi: 10.1007/s11154-018-9460-5. Rev Endocr Metab Disord. 2018. PMID: 30209646 Free PMC article. Review.
-
Creatine energy substrate increases bone density in the Pahenu2 classical PKU mouse in the context of phenylalanine restriction.Mol Genet Metab Rep. 2023 Aug 6;36:100996. doi: 10.1016/j.ymgmr.2023.100996. eCollection 2023 Sep. Mol Genet Metab Rep. 2023. PMID: 37588420 Free PMC article.
-
Evaluation of bone mineral density and biochemical markers in pediatric patients with phenylketonuria.Mol Genet Metab Rep. 2024 Dec 8;41:101173. doi: 10.1016/j.ymgmr.2024.101173. eCollection 2024 Dec. Mol Genet Metab Rep. 2024. PMID: 39720738 Free PMC article.
References
-
- National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000. Pediatrics. 2001;108(4):972–982. - PubMed
-
- Adamczyk P, Morawiec-Knysak A, Pludowski P, et al. Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria. J Bone Miner Metab. 2010;29(2):236–244. - PubMed
-
- Al-Qadreh A, Schulpis KH, Athanasopoulou H, et al. Bone mineral status in children with phenylketonuria under treatment. Acta Paediatr. 1998;87(11):1162–1166. - PubMed
-
- Allen JR, Humphries IR, Waters DL, et al. Decreased bone mineral density in children with phenylketonuria. Am J Clin Nutr. 1994;59(2):419–422. - PubMed
-
- Allen JR, Humphries IR, Waters DL, et al. Decreased bone mineral density in children with phenylketonuria. The American journal of clinical nutrition. 1994;59(2):419–422. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous